TRML Tourmaline Total Debt to Capital

The potential for excess profits for Tourmaline Bio, Inc. (TRML) depends on a successful antibody patent. The debt-to-equity trend displayed on GURU.Markets recorded a value of 0.00, confirming financial stability. Tourmaline Bio, Inc. (TRML) is capturing the thyroid therapy niche, while high R&D costs and stringent FDA requirements create an insurmountable barrier to entry for new players.

This ratio is calculated as the total borrowed liabilities relative to the company's equity. This metric determines the degree of financial leverage and the business's dependence on external financing. For Tourmaline Bio, Inc. (TRML), which is developing costly clinical trials for antibodies, low indebtedness is critical for maintaining operational flexibility. Patent protection for future products mitigates risks when raising capital. By analyzing this chart of the total liabilities-to-equity ratio, an investor assesses the sustainability of the company's development model.